Policies Affecting Drug Approval, Supply, and Cost

Core Concepts

Drug approval: the FDA pathway

In the United States, the Food and Drug Administration (FDA) must approve a drug before it can be marketed. The modern pathway typically works like this:

1. Preclinical testing: The drug is studied in the laboratory and in animals to gather initial safety and activity data.
2. Investigational New Drug (IND) application: The sponsor asks the FDA for permission to test the drug in humans.
3. Clinical trials in phases: Phase I studies focus on safety and dosing in a small number of people; Phase II studies look at effectiveness and appropriate dose in a larger group; Phase III studies confirm effectiveness and monitor side effects in large, often multi-site trials.
4. New Drug Application (NDA): The sponsor submits all the evidence; the FDA reviews it and decides whether the benefits outweigh the risks for the intended use.
5. Post-marketing (Phase IV): After approval, safety continues to be monitored in the real-world population, which is larger and more diverse than trial participants.

Generic drugs follow a shorter path. Under the Hatch-Waxman Act (1984), a manufacturer can file an Abbreviated New Drug Application (ANDA) showing that the generic is bioequivalent to the brand-name drug — absorbed at a similar rate and extent — rather than repeating full clinical trials. Biosimilars (for biologic drugs made from living systems) follow a separate pathway created by the Biologics Price Competition and Innovation Act (2009); because biologics are complex, their approval requires more evidence than a simple generic.

Safety monitoring continues after approval through systems such as the FDA Adverse Event Reporting System (FAERS) and MedWatch, the FDA's reporting portal for health professionals and the public. For drugs with serious risks, the FDA may require a Risk Evaluation and Mitigation Strategy (REMS) — extra safeguards such as restricted distribution, special monitoring, or required patient education.

Supply: manufacturing, scheduling, and shortages

Approval does not guarantee availability. Drug shortages occur when demand outstrips supply; common causes include manufacturing quality problems, shortages of raw ingredients, sudden demand spikes, and companies discontinuing older, less profitable products. The FDA and other agencies track shortages, and health systems respond with allocation policies, therapeutic alternatives, and careful stewardship — decisions made under institutional policy and with provider involvement, not by individual nurses acting alone.

Controlled substances are governed separately. The Controlled Substances Act (1970) established a schedule system (Schedules I–V) based on a drug's accepted medical use and its potential for abuse or dependence. Schedule I drugs have no accepted medical use and are not prescribable; Schedules II–V are prescribable with increasingly permissive rules. The Drug Enforcement Administration (DEA) enforces these rules, and nurses must know the documentation, storage, and waste requirements for controlled substances in their setting.

Cost: patents, competition, and payment systems

Drug prices are shaped by a mix of market forces and policy:

• Patents and exclusivity: A patent gives the manufacturer a temporary monopoly (roughly 20 years from filing, though effective market life is usually shorter). During this period there is no generic competition, which is how manufacturers recoup research costs — and why newer drugs are usually more expensive.
• Generic competition: When exclusivity ends, generics typically enter at much lower prices, which is why generic availability is the single most powerful force for affordability.
• Formularies and tiers: Insurers maintain lists of covered drugs (formularies) organized into tiers with different cost-sharing. A plan may require prior authorization, step therapy (trying a preferred drug first), or generic substitution to control costs. Rules vary widely by plan and state.
• Public programs: Medicare Part D provides outpatient drug coverage through private plans; Medicaid programs have their own coverage and rebate arrangements; the 340B program requires manufacturers to sell certain drugs at a discount to eligible safety-net hospitals and clinics.
• Negotiation and price policy: Federal and state governments continue to add levers, including measures allowing Medicare to negotiate prices for selected drugs (for example, provisions of the Inflation Reduction Act of 2022) and laws addressing price transparency. These policies are evolving, so always check current sources.

Nursing implications

• Safe administration: Verify the right drug, person, dose, route, and time; know look-alike/sound-alike drugs and high-alert medications per institutional policy.
• Generic vs. brand: Understand state and facility substitution rules; teach people that a generic may look different but contains the same active ingredient, while noting that substitution decisions follow prescriber and pharmacy policy.
• Cost conversations: Ask about affordability; refer to patient assistance programs, copay cards, and social services; document and communicate barriers to the care team.
• Adverse event reporting: Report suspected adverse effects through facility channels and, as appropriate, to MedWatch — reporting saves future patients.
• Shortage response: Follow the facility's shortage policy; never substitute or ration without orders and policy; communicate honestly with the person.
• Scope note: Prescribing, substitution, and treatment decisions belong to providers and payers; the nurse's role is verification, education, monitoring, reporting, and advocacy.

Common Confusions